<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077787</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1269-9921</org_study_id>
    <nct_id>NCT05077787</nct_id>
  </id_info>
  <brief_title>Tactile and Kinaesthetic Stimulation in Neonates With Hyperbilirubinaemia</brief_title>
  <official_title>Tactile and Kinaesthetic Stimulation in Preterm Neonates With Hyperbilirubinaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asir John Samuel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maharishi Markendeswar University (Deemed to be University)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperbilirubinemia is the commonest problem seen in neonates, owing to severe complications&#xD;
      in lifetime. The study design of the study is pretest - posttest experimental design.&#xD;
      Convenience Sampling will be used for recruiting the neonates. In study neonates will be&#xD;
      selected according to the selection criteria and will be allocated into two groups in 1: 1&#xD;
      ratio, Intervention group - neonates will receive tactile and kinesthetic stimulation for 15&#xD;
      minutes for 3 consecutive days, 1 hours after feed twice daily along with Phototherapy,&#xD;
      Control group - Phototherapy alone will be given. Total serum bilirubin and weight gain will&#xD;
      be assessed as outcome measure daily once. Transcutaneous bilirubin will be assessed before&#xD;
      and after every intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">August 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Serum Bilirubin (TSB)</measure>
    <time_frame>Changes in the TSB level will be measured at baseline and at the end of three days intervention</time_frame>
    <description>It will be measured to evaluate the total bilirubin level in neonates at baseline and the difference in bilirubin levels after giving the intervention on first, second and third day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcutaneous Bilirubin (TcB)</measure>
    <time_frame>Changes in the TSB level will be measured at baseline and at the end of three days intervention</time_frame>
    <description>TcB measurement is a non invasive method of measuring bilirubin levels in neonates with hyperbilirubinaemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight Gain</measure>
    <time_frame>Changes in the weight will be measured at baseline and at the end of three days intervention</time_frame>
    <description>Weight gain will be measured to evaluate the improvement in neonates after intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Neonatal Hyperbilirubinemia</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonates recruited in experimental group will receive massage therapy and kinaesthetic stimulation for 15 minutes along with phototherapy for consecutive days . It will be given in three phases first massage therapy will be given for 5 minutes, followed by movement of limbs for 5 minutes and then again massage therapy will be repeated for 5 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Neonates recruited in control group will receive phototherapy alone along with regular care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Massage therapy</intervention_name>
    <description>Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kinaesthetic stimulation</intervention_name>
    <description>Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. New born in Neonatal Intensive Care Unit&#xD;
&#xD;
          2. Stable vitals&#xD;
&#xD;
          3. Full Term and Preterm neonates&#xD;
&#xD;
          4. Gestational age 34 weeks to 40 weeks&#xD;
&#xD;
          5. Birth weight -1800 - 2500 g&#xD;
&#xD;
          6. APGAR Score at birth of 8 -10&#xD;
&#xD;
          7. Total serum bilirubin levels &gt; 5mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saumya Kothiyal, MPT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maharishi Markendeshawar (Deemed to be University)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saumya Kothiyal, PhD scholar</last_name>
    <phone>8650987709</phone>
    <email>saumyakothiyal28@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asir John Samuel, PhD</last_name>
    <phone>8059930222</phone>
    <email>asirjohnsamuel@mmumullana.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Rahmawati D, Sampurna MTA, Etika R, Utomo MT, Bos AF. Transcutaneous bilirubin level to predict hyperbilirubinemia in preterm neonates. Version 2. F1000Res. 2020 Apr 28 [revised 2020 Jan 1];9:300. doi: 10.12688/f1000research.22264.2. eCollection 2020.</citation>
    <PMID>33014346</PMID>
  </reference>
  <reference>
    <citation>Lin CH, Yang HC, Cheng CS, Yen CE. Effects of infant massage on jaundiced neonates undergoing phototherapy. Ital J Pediatr. 2015 Nov 25;41:94. doi: 10.1186/s13052-015-0202-y.</citation>
    <PMID>26607061</PMID>
  </reference>
  <reference>
    <citation>Field T. Pediatric Massage Therapy Research: A Narrative Review. Children (Basel). 2019 Jun 6;6(6). pii: E78. doi: 10.3390/children6060078. Review.</citation>
    <PMID>31174382</PMID>
  </reference>
  <reference>
    <citation>Niemi AK. Review of Randomized Controlled Trials of Massage in Preterm Infants. Children (Basel). 2017 Apr 3;4(4). pii: E21. doi: 10.3390/children4040021. Review.</citation>
    <PMID>28368368</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maharishi Markendeswar University (Deemed to be University)</investigator_affiliation>
    <investigator_full_name>Asir John Samuel</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

